Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.54 |
| ▸ | NPC1 | O15118 | 6/20 | 0.54 |
| ▸ | TP53 | P04637 | 4/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6938529 | 0.79 | NOTUM (0.61) | RAB9ANPC1TP53THRBMAPK1 | |
| SCHEMBL5157687 | 0.79 | RAB9A (0.61) | RAB9ANPC1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL16373542 | 0.79 | MAPK1 (0.55) | RAB9ANPC1TP53THRBMAPK1 | |
| SCHEMBL481400 | 0.79 | HSD17B1 (0.49) | RAB9ANPC1TP53ALDH1A1MAPT | |
| SCHEMBL16825991 | 0.79 | NPC1 (0.50) | RAB9ANPC1TP53THRBMAPK1 | |
| SCHEMBL17858736 | 0.79 | RAB9A (0.45) | RAB9ANPC1TP53ALDH1A1POLB | |
| SCHEMBL2486578 | 0.78 | PTPN1 (0.76) | RAB9ANPC1TP53THRBMAPK1 | |
| SCHEMBL1544808 | 0.78 | NOTUM (0.69) | RAB9ANPC1TP53THRBMAPK1 | |
| SCHEMBL17084388 | 0.77 | NPC1 (0.73) | RAB9ANPC1TP53MAPTSMN1; SMN2 | |
| Water SCHEMBL28785293 | 0.77 | HSD17B1 (0.44) | RAB9ANPC1TP53MAPK1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6005116-A | HAVE INHIBITION ACTIVITIES AGAINST TYPE A-MONOAMINE OXIDASE; TREATING OR PREVENTING DEPRESSION, PARKINSON'S DISEASE, ALZEHEIMER'S DEMENTIA, OR CEREBROVASCULAR DEMENTIA | SANKYO COMPANY, LIMITED (JP) | 1999-12-21 | — | — | US | disclosed |
| CN-1216986-A | Isoxazole derivatives | SANKYO CO (JP) | 1999-05-19 | — | — | CN | disclosed |
| EP-0885891-A1 | ISOXAZOLE DERIVATIVES | SANKYO COMPANY LIMITED (JP) | 1998-12-23 | — | — | EP | disclosed |
| US-5321037-A | Isoxazole derivatives for use as cerebro-active drugs and central muscle relaxants | SANKYO COMPANY, LIMITED (JP) | 1994-06-14 | — | — | US | disclosed |
| EP-0335723-B1 | ISOXAZOLE DERIVATIVES FOR USE AS CEREBRO-ACTIVE DRUGS AND CENTRAL MUSCLE RELAXANTS | Sankyo Company Limited (JP) | 1991-12-04 | — | — | EP | disclosed |
| EP-0335723-A1 | Isoxazole derivatives for use as cerebro-active drugs and central muscle relaxants | Sankyo Company Limited (JP) | 1989-10-04 | — | — | EP | disclosed |